Impact of β-Blockers on Huntington Disease Progression
Author Information
Author(s): Jordan L. Schultz, Amy C. Ogilvie, Lyndsay A. Harshman, Peg C. Nopoulos
Primary Institution: University of Iowa
Hypothesis
How does β-blocker use influence motor-diagnosis onset and progression rates in premanifest and early motor-manifest Huntington disease (HD)?
Conclusion
β-blocker therapy in HD was associated with a later age at onset and a slower rate of worsening of clinical symptoms.
Supporting Evidence
- β-blocker users had a lower annualized hazard of motor diagnosis in premanifest HD.
- β-blocker users showed slower annualized worsening in motor and cognitive symptoms in early motor-manifest HD.
- These findings suggest a therapeutic potential for β-blockers in Huntington disease.
Takeaway
This study found that taking β-blockers might help people with Huntington disease by delaying when they start showing symptoms and slowing down how quickly those symptoms get worse.
Methodology
This observational, longitudinal multicenter study used the Enroll-HD platform database, including propensity score–matched cohorts of patients with premanifest HD and early motor-manifest HD who were either users or nonusers of β-blockers.
Potential Biases
Selection biases may have occurred, as β-blocker use is likely more common in older individuals with more cardiovascular comorbidities.
Limitations
The results represent associations rather than causative changes induced by β-blockers, and the study did not evaluate dose-related effects of β-blockers.
Participant Demographics
Participants included 4683 patients with genetically confirmed preHD and 3024 with mmHD, with a mean age of 46.4 years for preHD and 58.9 years for mmHD.
Statistical Information
P-Value
0.02
Confidence Interval
95% CI, 0.46-0.94
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website